Jukka Westermarck

Passionate about yet uncapitalized potential of phosphatases and phosphoproteins as (breast) cancer therapy targets. "Nature selects for phenotype, not genotype"
This user account status is Approved

This user has not added any information to their profile yet.

Centre for Biotechnology, University of Turku
Breast cancer, therapy resistance, Protein Phosphatase 2A (PP2A), CIP2A, MYC, RAS, phosphoproteomics, phosphorylation dependent signalling, patient stratification, basal-like breast cancer, Her2,
PP2A, CIP2A, TNBC, phosphoproteomics
MS proteomics, RNA sequencing, Tissue microarrays, drug response screens, RNAi, viral gene transduction, western blot, systems biology
Cell culture, mammospheres, CIP2A knock-out mouse models, xenografts